Skip to content

MDMA research published in 2023

Page 3 of 7: studies 41 to 60 of 125, newest first. Back to the MDMA overview

Studies

Mdma and Methamphetamine: An Investigation of a Neurochemical and Behavioral Cross-Tolerance in the Rat

Scholarworks (University of Massachusetts Amherst) August 15, 2023 Christina S. Henderson

We previously found that intermittent administration of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) to adolescent male rats protected against the behavioral and serotonergic neurotoxic effects of a subsequent MDMA binge. Similar results have been reported for the dopamine (DA) neurotoxin methamphetamine (METH). The present study tested the hypothesis that intermittent adolescent MDMA...

use of 3,4-Methylenedioxymethamphetamine (MDMA) in the treatment of Post-Traumatic Stress Disorder (PTSD) - review

Journal of Education, Health and Sport August 15, 2023 Karol Womperski, Rafał Bogacz, Magdalena Gaik et al. 1 citation

Introduction: Post-traumatic stress disorder (PTSD) is a common health issue of complex etiology significantly deteriorating functioning in everyday life. It may develop as a result of exposure to traumatic events like traffic accidents, war experience, sexual abuse and domestic violence. Current methods of treatment consist of trauma-oriented psychotherapy supported by selective serotonin...

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Journal of Psychopharmacology August 12, 2023 Michael Tagen, Daniel Mantuani, Alex Holstein et al. 39 citations

Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...

The Depths of Ecstasy

Routledge eBooks August 11, 2023 Douglas Thomas

BDSM and kink practitioners sometimes describe scenes that induce altered dream-like states with blurred boundaries and vivid transcendent imagery. Firsthand accounts illustrate the intensity and transformational character of such experiences, which can be characterized as ecstatic. The activities of alternative sexualities are a modern iteration of humanity’s archetypal fascination with...

Locomotor and discriminative stimulus effects of three benzofuran compounds in comparison to abused psychostimulants

Drug and Alcohol Dependence Reports August 10, 2023 Rebecca D. Hill, Ritu A. Shetty, Nathalie Sumien et al. 4 citations

Aims: Benzofurans are used recreationally, due their ability to cause psychostimulant and/or entactogenic effects, but unfortunately produce substantial adverse effects, including death. Three benzofurans 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB), 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-MAPB) and 6-(2-aminopropyl) benzofuran (6-APB) were tested to determine their behavioral effects in...

Behavioral metabolomics: how behavioral data can guide metabolomics research on neuropsychiatric disorders.

Metabolomics : Official journal of the Metabolomic Society August 2, 2023 Ross Van de Wetering, Jan A Vorster, Sophie Geyrhofer et al. 4 citations

Metabolomics produces vast quantities of data but determining which metabolites are the most relevant to the disease or disorder of interest can be challenging. This study sought to demonstrate how behavioral models of psychiatric disorders can be combined with metabolomics research to overcome this limitation. We designed a preclinical, untargeted metabolomics procedure, that focuses on the...

Therapeutic effects of methimazole on 3,4-methylenedioxymethamphetamine-induced hyperthermia and serotonergic neurotoxicity.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie August 1, 2023 I-Hsun Li, Tsung-Ta Liu, Ying-Chen Chen et al.

3,4-methylenedioxymethamphetamine (MDMA) is a popular recreational drug, however over 200 studies demonstrate that acute (e.g. hyperthermia, rhabdomyolysis) and chronic (e.g. neurotoxicity) toxicity effects of MDMA were observed in different animals. Methimazole (MMI), an inhibitor of thyroid hormone synthesis, was found to significantly reduce the HSP72 expression of heat stress induced in...

Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol

Frontiers in Psychiatry July 15, 2023 M. Kati Lear, Sarah M. Smith, Brian Pilecki et al. 14 citations

BackgroundSocial anxiety disorder (SAD) is a serious and prevalent psychiatric condition that heavily impacts social functioning and quality of life. Though efficacious treatments exist for SAD, remission rates remain elevated and a significant portion of those affected do not access effective treatment, suggesting the need for additional evidence-based treatment options. This paper presents a...

DOI: 10.3389/fpsyt.2023.1083354 (opens in new tab) Full text (opens in new tab) Social anxiety disorder Psychedelic research Clinical trial protocol Psychedelic assisted therapy +4

Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics

British medical journal July 11, 2023 B. Nogrady 18 citations

The TGA attached conditions to their use: namely, that onlypsychiatristswhoare trainedandauthorised to prescribe MDMA and psilocybin can do so, that a human research ethics committeemust approve each patient case, and that the treatments must be used in conjunction with psychotherapy.1 An officer of the TGA and the ethics committee must also satisfy themselves that “a suitably robust treatment...

Synthesis of R- and S-MDMA via nucleophilic ring-opening of homochiral N-tosylaziridines

Australian Journal of Chemistry July 11, 2023 Katie D. Lewis, Glenn A. Pullella, Han Chern Loh et al. 2 citations

Homochiral (R)- and (S)-3,4-methylenedioxymethamphetamine (MDMA) were prepared in six steps (each) from the chiral pool precursors d- and l-alanine, respectively. The key step, copper-catalysed regioselective ring-opening of an N-tosylaziridine with an aryl Grignard reagent, proceeded in high yield with complete regioselectivity. Elaboration was achieved with preservation of configurational...

DOI: 10.1071/ch23064 (opens in new tab) Regioselectivity Enantioselective synthesis Enantiomer Ring chemistry +9

Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study

Frontiers in Psychiatry July 11, 2023 Gniewko Więckiewicz, Iga Stokłosa, Maciej Stokłosa et al. 2 citations

Introduction Attention-deficit/hyperactivity disorder (ADHD) was originally treated as a neurodevelopmental disorder that occurs mainly in children and tends to diminish or disappear with age, but we now know that symptoms persist into adulthood in over 50% of ADHD patients. Undiagnosed individuals often turn to psychoactive substance to minimize the negative aspects of functioning and improve...

DOI: 10.3389/fpsyt.2023.1184023 (opens in new tab) MDMA Ecstasy Psychoactive substance Methylphenidate +4

Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial.

The lancet. Diabetes & endocrinology July 2023 Cihan Atila, Friederike Holze, Rakithan Murugesu et al.

Disruptions of the hypothalamic-pituitary axis can cause an arginine vasopressin deficiency, also known as central diabetes insipidus. Patients with this condition are at high risk of additional oxytocin deficiency owing to the close anatomical proximity of oxytocin-producing neurons; however, no conclusive evidence for such a deficiency has been reported. We aimed to use...

A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder.

Focus July 1, 2023 Benjamin R. Lewis, Kevin Byrne 9 citations

Posttraumatic stress disorder (PTSD) is a common chronic and disabling psychiatric disorder that may develop after exposure to a traumatic life event. There are existing evidence-based psychotherapies and pharmacotherapies for PTSD; however, these treatments have significant limitations. 3,4-methylenedioxymethamphetamine (MDMA) was granted "breakthrough therapy" status by the U.S. Food and Drug...

The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review.

Neuroscience & Biobehavioral Reviews July 1, 2023 Manoj K. Doss, Harriet de Wit, David A Gallo 30 citations

Psychoactive drugs modulate learning and emotional processes in ways that could impact their recreational and medical use. Recent work has revealed how drugs impact different stages of processing emotional episodic memories, specifically encoding (forming memories), consolidation (stabilizing memories), and retrieval (accessing memories). Drugs administered before encoding may preferentially...

MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2023 Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. 97 citations

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.

FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2023 Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski et al. 24 citations

Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for...

The need for establishing best practices and gold standards in psychedelic medicine.

Journal of Affective Disorders July 1, 2023 Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price et al. 38 citations

Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the...

FDA issues first draft guidance on psychedelic research

Mental Health Weekly June 30, 2023 Valerie A. Canady

Observing that designing clinical studies to evaluate the safety and effectiveness of psychedelic substances presents a number of unique challenges that require careful consideration to the industry, the U.S. Food and Drug Administration (FDA) last month issued, for the first time, draft guidance for conducting clinical trials with psychedelic drugs such as psilocybin and MDMA (ecstasy).